While just a small part of Cardinal Health‘s (NYSE:CAH) $100 billion-plus revenue, the nuclear medicine business is an important driver of higher margins for the drug distribution company. In particular, positron emission tomography (PET) radiopharmaceuticals — which are used to aid in imaging scans for cancer, heart disease and brain disorders — are poised to […]
Cardinal Health (NYSE:CAH) sees a big growth opportunity in the specialty drugs distribution market, but catching up with its top two rivals could be a tough slog. Specialty drugs are typically complex, injectable biologics that are used to treat somewhat small groups of patients for specific conditions like multiple sclerosis, cystic fibrosis and certain types […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Drug distributor Cardinal Health (NYSE: CAH) reported a 19 percent fourth-quarter increase in sales of generic drugs, an area that continues to be a strength for the company. Generics — as well as acquisitions that have allowed the company to sell more generics — contributed to a 9 percent increase in fourth-quarter revenue to $26.8 […]
Pharmaceuticals distributor Cardinal Health (NYSE: CAH) has opened a molecular imaging center with the goal of developing new radioactive imaging agents that will help doctors treat a wide range of diseases like cancer, heart disease and neurological disorders. Cardinal scientists, engineers and manufacturing experts will work with clients in the pharmaceutical and academic research industries […]
Once an early high-profile supporter of the medical mart concept, drug distributor Cardinal Health (NYSE:CAH) has had an apparent change of opinion. The giant drug distributor – and Ohio’s largest company – does not plan to lease space in the planned Cleveland medical mart or its counterpart in Nashville, spokeswoman Corey Kerr said. So don’t […]
The capital punishment-opposing nun prominently featured in the movie “Dead Man Walking” has asked Cardinal Health (NYSE: CAH) to recall a drug that’s used in the execution of prisoners. But Sister Helen Prejean isn’t likely to be pleased with the response from the Dublin, Ohio-based pharmaceuticals distributor. A Cardinal spokeswoman was asked multiple times whether […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medical products supplier Cardinal Health (NYSE:CAH) raised its full-year earnings expectations, driven in part by a 25 percent increase in third-quarter profits in its pharmaceutical business. Dublin, Ohio-based Cardinal now expects adjusted full-year earnings per share from continuing operations between $2.61 and $2.67, according to a statement from the company. CEO George Barrett cited strong […]
After a little more than a year on the job, a Cardinal Health (NYSE:CAH) board member is stepping down for health reasons. Dr. James Mongan’s resignation comes “due to health-related reasons,” and “is not the result of any disagreement with [Cardinal] on any matter relating to the [its] operations, policies or practices,” according to a […]
Cardinal Health (NYSE:CAH) and pharmaceuticals distributors of its ilk will have few better friends over the coming years than generic drugs. The so-called “generic wave” — created by scores of brand-name drugs whose patents are expiring between this year and 2015 — is expected to be a huge boon to drug wholesalers like Dublin, Ohio-based […]
As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) marches toward FDA approval of its “game-changing” radiopharmaceutical Lymphoseek and its share price continues to climb, many of the company’s shareholders are likely wondering when they’ll get the chance to cash out. There’s certainly plenty of investor interest in the company. Neoprobe’s shares are up a whopping […]
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Drug distributor Cardinal Health (NYSE:CAH) raised its earnings outlook for 2011 after it reported an 11 percent increase in the profits of its pharmaceuticals business unit in its fiscal second quarter.
As generic drugs increasingly replace brand names in the coming years, pharmaceuticals wholesalers like Cardinal Health (NYSE:CAH) will see their operating profits rise "dramatically," according to a report from Barclays Capital.
Cardinal Health (NYSE: CAH), Ohio's largest company by revenues, led the state's health organizations in federal lobbying spending last year at nearly $1.3 million. Cardinal, a pharmaceuticals distributor and medical products supplier, upped its federal lobbying spending by 39 percent over the prior year, publicly filed lobbying reports revealed.
Cardinal Health (NYSE:CAH) renewal of a key drug distribution contract with Walgreen Co. earlier this month brings renewed focus on just how heavily reliant Cardinal is on its top two customers. In Cardinal's fiscal 2010, Walgreen (24 percent) and CVS (22 percent) combined for a 46 percent share of revenues. That's up from a combined 43 percent in 2008. Adam Fein, a pharmaceutical industry consultant with Pembroke Consulting, stated on his blog Drug Channels: "The data show a company that's increasingly at the mercy of its two dominant customers."
Most people in Ohio's biomedical industry would've considered 2010 a good year if just one key thing happened -- voters renewed the state's $1.35 billion, 10-year Third Frontier program, which is designed to energize Ohio’s economy by investing in cutting-edge technology. It happened and heads up MedCity News' list of the biggest highlights of the year for Ohio's biomedical industry.